In 2005, Randy Moritz was diagnosed with polycystic kidney disease. Fifteen years later, doctors told him he needed a transplant and removed both his kidneys. His wife, Karen, was a match and the surgery was booked for March 2020... But then COVID-19 hit.

BK Polyomavirus and thrombotic microangiopathy (TMA) are significant complications following stem cell transplantation, leading to serious health risks. In this presentation, Dr. Ben Laskin, Dr. Sonata Jodele, and Dr. Steve Kleiboeker discuss the current understanding of these conditions and highlight gaps in knowledge and treatment strategies. While advances have been made in diagnosing and managing BK virus-related complications, unmet needs remain in effectively addressing TMA. The presentation underscores the importance of continued research and collaboration to improve patient outcomes.

A leader in the industry, Dr. Ferrara’s career has focused on the immunology of BMT, particularly its major complication GVHD. Using innovative proteomic techniques, his team has identified and validated biomarkers for skin, gut and steroid-resistant GVHD. Eurofins Viracor is exclusively partnering with Dr. Ferrara to utilize the approach developed by Drs. Ferrara and Levine and the Mount Sinai Acute GVHD International Consortium (MAGIC).

This video delves into the biology of the biomarkers utilized in the aGVHD Algorithm assays, providing a foundational understanding of their role in assessing aGVHD risk. It explains how MAGIC Algorithm Probability (MAP) testing classifies patients based on their long-term risk of severe graft versus host disease (GVHD) and non-relapse mortality, focusing on various patient stages: pre-symptomatic, symptom onset, and post-treatment after hematopoietic cell transplantation (HCT). Additionally, the series covers the interpretation of MAPs as response biomarkers, helping clinicians gauge treatment efficacy. Finally, it presents case studies that recommend treatment approaches guided by MAPs, demonstrating the practical application of these insights in clinical settings.

This video provides valuable guidance on interpreting changes in the MAGIC Algorithm Probability (MAP) for acute graft versus host disease (aGVHD), emphasizing its significance in effective clinical decision-making. It highlights the importance of MAP results in assessing patient conditions and understanding their potential risks. The series also explores how the use of multiplexed assessment of biomarkers (MAP) can enhance patient care by enabling more tailored treatment strategies. Ultimately, the integration of these biomarkers into clinical practice can lead to improved treatment outcomes for patients facing aGVHD.

This video explores thrombotic microangiopathy (TMA) and its intricate relationship with acute graft versus host disease (aGVHD), shedding light on this important complication in transplant patients. It discusses the causes of complications of disease (COD) that can arise in these patients, emphasizing the need for effective monitoring. Key serum biomarkers used to monitor aGVHD are highlighted, illustrating how these markers can indicate disease severity and treatment response. The series also addresses the limitations of relying solely on clinical symptoms, noting that there can be significant mismatches between clinical findings and biomarker results. Factors contributing to these discrepancies are examined, underscoring the importance of integrating biomarker data into clinical practice for better patient management.